Zoetis Shares Soar 1.78% on Strong Q2 Results Surpassing $510M Trading Volume to Top Daily Rankings

Zoetis (ZTS) shares rose 1.78% on August 13, with a trading volume of $510 million, a 31.39% increase from the previous day, reflecting investor attention following its Q2 results. The company reported $2.46 billion in revenue, exceeding estimates by 1.9%, and delivered adjusted earnings of $1.76 per share, a 9.2% beat. Management raised full-year revenue guidance to $9.53 billion, citing strength in core franchises and international expansion.

Strong performance in the Simparica and Key Dermatology segments drove operational growth, with Simparica Trio showing resilience despite competition. The Key Dermatology portfolio, including Apoquel and Cytopoint, saw double-digit growth, supported by high adoption rates in international markets. However, the osteoarthritis pain product Librela faced slower-than-expected uptake, particularly in the U.S., due to safety concerns and the need for further clinical validation. Management emphasized ongoing investments to address these challenges.

Operating margins improved to 39%, driven by pricing discipline and cost management. CFO Wetteny Joseph noted margin gains would continue as manufacturing costs normalize but warned of potential headwinds from new competitors and macroeconomic uncertainty. The company anticipates annual major product approvals to fuel growth, with a focus on long-acting therapies for chronic conditions.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.46% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management in such a volatile scenario.